Hemophilia Market Size, Share, Trends, Industry Overview, Top Players - Pfizer, uniQure N.V., CSL, Genentech USA, Sanofi

Hemophilia Market Report size & scope :
The SNS Insider report indicates that the Hemophilia Market was valued at USD 13.62 billion in 2022, and is expected to reach market size of USD 20.43 billion by 2030, with a compound annual growth rate (CAGR) of 5.2% expected over the forecast period from 2023 to 2030.

The report provides a detailed analysis of the company profiles of key organizations operating in the global hemophilia market, as well as a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development and innovations, recent developments, joint ventures, partnerships, mergers and acquisitions, strategic alliances, SWOT analysis, and key financial information. This aids in determining the overall competition in the market setting.

Major Key Players:
-Pfizer
-uniQure N.V CSL
-Genentech USAInc
-Sanofi
-Takeda Pharmaceutical Company Limited
-Baxalta
-Bayer
-Novo Nordisk
-Alnylam Pharmaceuticals
-Biogen and Other Players

Get a Free Sample of Report @ https://www.snsinsider.com/sample-request/2705

Hemophilia Market Opportunities:
Technological advancement in the treatment of hemophilia
The rise in technological advancement as a result of the increasing demand for the treatment of hemophilia disease is the major driving factor, as is the continued innovation that will assist health experts in providing proper treatment to patients, as well as the focus on future upgrades, which will drive the market during the forecasted period.

Segmentation Analysis in Hemophilia Market:
Based on type, in 2022, Hemophilia A had the highest hemophilia market share at 74.16%. It is a hereditary condition that results in a deficiency of blood clotting factor VIII. The high prevalence of hemophilia A in developed nations, as well as supportive government activities to introduce medications in important markets such as the United States, Europe, and Japan, contribute to this dominance. According to WFH's 2020 survey, countries such as the United States, India, and Brazil lead with 10,000 type A cases.

On the basis of distribution channel, in 2022, the specialty pharmacy category led the hemophilia market, accounting for 61.4%. Hemophilia is an uncommon and difficult illness, and there are few skilled experts who can provide hemophilia treatment. The majority of hemophilia patients in the United States are treated at "hemophilia treatment centers," sometimes known as HTCs. Most HTCs have interdisciplinary teams that are experienced in hemophilia management and get the majority of their drugs from specialty pharmacies.

Key Market Segmentation:

By Therapy Type
-Replacement Therapy
-Clotting Factors
-Plasma-derived factor concentrate
-Recombinant factor concentrate
-Medications
-Hemlibra
-DDAVP/Stimate
-Amicar
-Fibrin Sealants
-Others
-Physical Therapy
-Immune Tolerance Induction (ITI) Therapy
-Vaccination
-Gene Therapy
-Others

By Indications
-Type A
-Type B
-Type C
-Type D

Key Regional Development in Hemophilia Market:
North America was the largest revenue-generating region in the hemophilia market in 2022, accounting for 49.81% of the total, owing to the presence of key players, increasing patient treatment adoption, favorable funding assistance, the presence of dedicated hemophilia treatment centers, and the disorder's rising prevalence. According to a 2021 article released by the National Hemophilia Foundation, the United States has approximately 25,000 persons with hemophilia, yet treatment can cost up to USD 270,000 per claimant every year.

Europe is predicted to grow at a 7.4% CAGR during the forecast period, owing to the region's increased prevalence of hemophilia and regulatory support for innovative product approval. For example, in February 2023, the European Commission approved Hemgenix, a new gene therapy, to treat hemophilia B. UniQure Inc. manufactures the product, while CSL Behring develops and distributes it. This approval is expected to mark a significant shift in the paradigm of hemophilia B patient treatment, alleviating the burden of life-long infusions.

Make an Enquiry of Report @ https://www.snsinsider.com/enquiry/2705

Key Takeaway from Hemophilia Market Study:
-Potential growth possibilities, as well as a penetration rate study of the products (market-related, i.e., the global hemophilia market), are discussed in order to understand the adoption rate and evaluate market size.

-The SWOT analysis examines both positive and negative aspects of market development that influence a company's growth and development in order to continue and survive over time.

Recent Development Related to Hemophilia Market:
-In February 2023, The FDA has approved Sanofi's once-weekly Factor VIII replacement medicine, ALTUVIIIO, for the on-demand and prophylactic treatment of hemophilia A.

-In May 2022, Precision Biologic launched the CRYOcheck Chromogenic Factor IX assay in Canada, the EU, Australia, and New Zealand following approval by their national health authorities. It was designed to detect FIX activity in hemophilia B patients.

-In November 2022, UniQure announced the launch of the first hemophilia B gene treatment, Hemgenix, in 2023 at a cost of $3.5 million. It has been cleared by the United States government and is scheduled to launch in 2023.

Buy Report @ https://www.snsinsider.com/checkout/2705

Table of Contents:
1.Introduction
2.Research Methodology
3.Market Dynamics
4.Impact Analysis
5.Value Chain Analysis
6.Porter's 5 forces model
7.PEST Analysis
8.Hemophilia Market Segmentation, By Therapy Type
9.Hemophilia Market Segmentation, by Indications
10.Regional Analysis
11.Competitive Landscape
12.USE Cases and Best Practices
13.Conclusion

Akash Anand - Head of Business Development & Strategy,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

info @ snsinsider.com,

Website: https://www.snsinsider.com/

Read our other Healthcare Related Report

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

This release was published on openPR.